Intravascular delivery of nucleic acid
View Patent ↗Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell.
1. A process for delivering an oligonucleotide complexed with a compound into an extravascular muscle cell of a mammal, comprising:
a) mixing the oligonucleotide and a polymer to form a complex wherein the zeta potential of the complex is not positive;
b) inserting the oligonucleotide into a mammalian blood vessel, in vivo;
c) increasing the permeability of the blood vessel;
d) passing the complex through the blood vessel; and,
e) delivering the complex into the mammalian muscle cell.
2. The process of claim 1 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
3. The process of claim 2 wherein increasing the pressure consists of increasing a volume of fluid within the vessel.
4. The process of claim 3 wherein increasing the volume consists of inserting the oligonucleotide in a solution into the vessel.
5. The process of claim 1 wherein the muscle cell consists of a skeletal muscle cell.
6. The process of claim 4 wherein the skeletal muscle cell consists of a limb muscle cell.
7. The process of claim 1 wherein the blood vessel consists of a cardiac blood vessel.
8. The process of claim 7 wherein the muscle cell consists of a cardiac muscle cell.
9. The process of claim 1 wherein the polymer is selected from the group consisting of histone, polyethyleneimine, modified polyethyleneimine, cationic lipid, poly-L-lysine, histone-lipid, histone-polyamine, and protamine.
10. The process of claim 1 wherein the zeta potential of the complex is negative.
11. An in vivo process for delivering a naked nucleic acid to an extravascular cell in a limb of a mammal, comprising:
a) forming a pharmaceutically acceptable solution containing the naked nucleic acid;
b) inserting an injection device into a vessel in the limb;
c) applying a device to occlude blood flow externally around the limb;
d) occluding blood flow to and from the limb; and,
e) injecting the solution through the injector into the vessel thereby increasing permeability of the blood vessel, passing the nucleic acid though the blood vessel and delivering the nucleic acid to the extravascular cell.
12. The process of claim 11 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
13. The process of claim 12 wherein increasing the pressure consists of increasing a volume of fluid within the vessel.
14. The process of claim 11 wherein said device for impeding blood flow is selected from the group consisting of: tourniquet, double tourniquet, double cuff tourniquet, cuff, sphygmomanometer, oscillotonometer, oscillometer, and haemotonometer.
15. The process of claim 11 wherein the nucleic acid consists of a polynucleotide.
16. The process of claim 11 wherein the nucleic acid consists of an oligonucleotide.
17. The process of claim 11 wherein the nucleic acid is selected from the list consisting of RNA, double strand RNA, siRNA, microRNA, and antisense nucleic acid.
18. The process of claim 11 wherein the extravascular cell consists of a muscle cell.
19. The process of claim 18 wherein the muscle cell consists of a leg muscle cell.
20. The process of claim 18 wherein the muscle cell consists of a foot muscle cell.
21. The process of claim 18 wherein the muscle cell consists of an arm muscle cell.
22. The process of claim 18 wherein the muscle cell consists of an hand muscle cell.